Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Launched by UNIVERSITY HOSPITAL, ROUEN · Aug 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to understand the genetic changes in patients with two specific conditions: Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). Currently, there are no targeted treatments for these conditions, and researchers hope that by studying the genes involved, they can find new ways to treat these diseases more effectively.

To participate in this trial, you would need to be an adult who has either MM or MGUS, which means you have specific levels of abnormal cells or proteins in your blood. The trial is open to people aged 65 and older, and you must be a member of a social security scheme. If you decide to join, you will be provided with detailed information about the study, and you’ll need to sign a consent form to show that you understand what it involves. Please note that individuals who are under legal guardianship cannot participate in this study. The trial is not currently recruiting participants, but it aims to help improve future treatments for these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
• • Membership of a social security scheme
• • Adult having read and understood the information letter and signed the consent form
• Exclusion Criteria:
• • Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship